Abstract
The activity of garenoxacin was assessed against 412 Streptococcus pneumoniae isolates (49.3% from the adult population). Overall penicillin, erythromycin, and ciprofloxacin (MIC, >/=4 micro g/ml) resistance was 51.7, 35.4, and 1.5%, respectively. For all isolates, the garenoxacin MIC was </=1 micro g/ml. Amino acid replacements in GryA (Ser81-->Phe or Tyr), ParC (Ser79-->Phe or Tyr; Asp83-->Gly; Lys137-->Asn), and ParE (Ile460-->Val; Asp435-->Asn), alone or in combination, were ascribed to the reduced garenoxacin susceptibility (MIC range, 0.5 to 1 micro g/ml) found in four isolates. The low impact of these mutations on garenoxacin activity envisages the possible coverage of S. pneumoniae populations resistant to preexisting quinolones.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Infective Agents / pharmacology*
-
DNA Gyrase / drug effects
-
DNA Gyrase / genetics
-
DNA Topoisomerases / metabolism*
-
DNA, Bacterial / genetics
-
Drug Resistance, Bacterial
-
Fluoroquinolones*
-
Genes, Bacterial / genetics
-
Humans
-
Indoles / pharmacology*
-
Methyltransferases / genetics
-
Microbial Sensitivity Tests
-
Pneumococcal Infections / epidemiology
-
Pneumococcal Infections / microbiology*
-
Prospective Studies
-
Quinolones / pharmacology*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Spain / epidemiology
-
Streptococcus pneumoniae / drug effects*
-
Streptococcus pneumoniae / enzymology
-
Streptococcus pneumoniae / genetics
Substances
-
Anti-Infective Agents
-
DNA, Bacterial
-
Fluoroquinolones
-
Indoles
-
Quinolones
-
Methyltransferases
-
rRNA (adenosine-O-2'-)methyltransferase
-
DNA Topoisomerases
-
DNA Gyrase
-
garenoxacin